AstraZeneca PLC (AZN)
NASDAQ: AZN · Real-Time Price · USD
73.00
+2.52 (3.58%)
At close: Jul 23, 2025, 4:00 PM
72.52
-0.48 (-0.66%)
After-hours: Jul 23, 2025, 7:52 PM EDT
AstraZeneca Revenue
AstraZeneca had revenue of $13.59B in the quarter ending March 31, 2025, with 7.17% growth. This brings the company's revenue in the last twelve months to $54.98B, up 15.48% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$54.98B
Revenue Growth
+15.48%
P/S Ratio
4.08
Revenue / Employee
$583,054
Employees
94,300
Market Cap
224.54B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
Thermo Fisher Scientific | 43.21B |
AZN News
- 17 hours ago - Five years after COVID, pharma shares languish in US policy limbo - Reuters
- 1 day ago - 5 Ideal "Safer" Dividend Buys From Bloomberg's July Watch List - Seeking Alpha
- 1 day ago - AstraZeneca announces $50 billion investment in U.S. as Trump's tariffs loom - Fast Company
- 1 day ago - AstraZeneca Plans to Invest $50B in US Manufacturing and Research by 2030 - Investopedia
- 1 day ago - AstraZeneca to build new Virginia plant as it re-hashes other U.S. investment plans - Market Watch
- 1 day ago - AstraZeneca commits $50B to US expansion amid Trump tariff pressure - Invezz
- 2 days ago - AstraZeneca to invest $50 billion in the U.S. as pharma tariffs weigh - CNBC
- 2 days ago - AstraZeneca to invest $50bn in US by 2030 amid Trump tariff threats - The Guardian